The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update. - Wikidata - awgldk - TriplyDB

The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update.

The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update.

http://www.wikidata.org/entity/Q38101044

about

Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth Sensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy.STAT3 in Cancer-Friend or Foe?Crosstalk between microRNA and DNA Methylation Offers Potential Biomarkers and Targeted Therapies in ALK-Positive Lymphomas Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma.The use of cellular thermal shift assay (CETSA) to study Crizotinib resistance in ALK-expressing human cancers.High expression of β-catenin contributes to the crizotinib resistant phenotype in the stem-like cell population in neuroblastoma.Novel Molecular Challenges in Targeting Anaplastic Lymphoma Kinase in ALK-Expressing Human Cancers.The absence of a novel intron 19-retaining ALK transcript (ALK-I19) and MYCN amplification correlates with an excellent clinical outcome in neuroblastoma patients.The Pathological Spectrum of Systemic Anaplastic Large Cell Lymphoma (ALCL).Refractory ALK-Positive Anaplastic Large Cell Lymphoma: Long Term Survival with Crizotinib

P2860

Q36106068-88F2CBCA-99EA-4361-86F6-9D3A78A59F04 Q36145016-A6C61711-7D3B-49A3-A8BA-9A05C2FCB192 Q38226313-80B8C3F2-7E10-4B68-A6CA-7335DBF0C37B Q38644718-B075316D-E8CA-41E3-BECC-0C01D41E1803 Q38858006-53C0AEBB-DA55-476A-A129-46E82483340B Q41116766-FC24C929-82C5-43C7-8059-A5EBC448BE1D Q47107337-028D32F5-8022-4A7D-9507-C0E3611B8559 Q47134648-1D819196-AC75-4EC9-8322-D6DE84B22231 Q51734147-D09C12A2-9C2B-4C38-9102-656397F19432 Q54117760-01B4F17F-B8D5-47AA-A28E-074B66CE3A13 Q56524606-D768C05B-4A8E-46E7-9194-5F9299794A29

P2860

The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update.

http://www.wikidata.org/entity/Q38101044

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update.

@en

type

label

The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update.

@en

prefLabel

The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update.

@en

P1433

Q38101044-9A6C0C10-180D-4E66-8A2F-E05A97C33907

P1476

Q38101044-245701EE-26D3-49BC-8CC6-6E23E09FAC6C

P2093

Q38101044-311D4981-0DB3-4291-BEBA-FA32A90C614B

Q38101044-39868FA1-324C-46F9-986A-2E96A0EAF701

P2860

Q38101044-0A9EA480-EF9E-4B35-BA68-E0523C2E9E78

Q38101044-11512845-D469-4E81-9D92-05C6F0A0A215

Q38101044-134732FD-CFF6-4CB1-856B-133CD7DBEF9D

Q38101044-1722D638-AF1F-4562-BB31-4C5934613DD2

Q38101044-17C12668-0927-4329-B4F5-E76A325FCF86

Q38101044-1C13475C-F000-4EF4-93DA-B925FE9EA7D5

Q38101044-2082961D-A63F-444C-B5D0-341097393BF2

Q38101044-20B55A9F-0A46-484B-93EE-E87496591805

Q38101044-2440E8AC-5D65-4AE6-BB39-6308299D8700

Q38101044-2789E4A5-F2BB-4896-9749-9CFE12E6AABD

P304

Q38101044-6BABD223-7417-4923-99F5-207B1477DF69

P31

Q38101044-1DEFE880-924B-4D78-B066-632A8374EAD2

P356

Q38101044-337934CB-25C5-4A1F-A4A2-731144ACCB29

P433

Q38101044-07714E71-D5D4-49C7-B369-AF4C6E1FBD0E

P478

Q38101044-ABC96111-062A-470B-B42E-117F099592E3

P577

Q38101044-FDE946B8-9AD8-430E-AD3E-DB4DF79F75B6

P5875

Q38101044-281E35BD-B09E-4B00-B1D6-2809282F53C6

P698

Q38101044-A112BFD9-D834-4DB1-B2D3-EE6AEE644658

P932

Q38101044-02144D3D-ACF2-4E95-BD92-D35837541D41

P356

2040620712471553

P1433

Therapeutic advances in hematology

P1476

The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update.

@en

P2093

Raymond Lai

http://www.w3.org/2001/XMLSchema#string

Robert J Ingham

http://www.w3.org/2001/XMLSchema#string

P2860

Immunoaffinity profiling of tyrosine phosphorylation in cancer cells

Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation

Anaplastic lymphoma kinase: signalling in development and disease

Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5)

Hypoxia-inducible factors and the response to hypoxic stress

Emerging importance of ALK in neuroblastoma

Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis

Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death

Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex

Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamy

P304

119-131

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/2040620712471553

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236267495

http://www.w3.org/2001/XMLSchema#string

P698

23610619

http://www.w3.org/2001/XMLSchema#string

P932

3629756

http://www.w3.org/2001/XMLSchema#string